Can a smartphone app detect Covid? Pfizer throws down $116M to find out
What can a cough say about a patient’s illness? Quite a bit, according to ResApp Health — and Pfizer’s listening.
The pharma giant is shelling out about $116 million ($179 million AUD) to scoop up the University of Queensland spinout and its smartphone technology that promises to diagnose Covid and other respiratory illnesses based on cough and breathing sounds, the university announced last week.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.